Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient

Abstract

The M. parascrofulaceum strain isolated in China was sensitive to rifabutin, rifapentine, clarithromycin, azithromycin, cefoxitin, and moxifloxacin. The mycobacteria were capable of proliferating in mice and could lead to pathological changes in the lungs of the mice.

Pulmonary <i>Mycobacterium parascrofulaceum</i> Infection in a Patient with Chronic Progressive Pulmonary Aspergillosis: A Case Report and Literature Review

“…Antimycobacterial agents are widely used for NTM treatment. CAM, RFP, and newly developed quinolones (especially moxifloxacin) are reportedly considered to be key drugs for pulmonary M. parascrofulaceum infection treatment ( 4 , 7 , 10 ). There have been no established treatments for M. parascrofulaceum .…”

“…The precise identification of mycobacterial species is important because the clinical courses and treatments vary according to the species. To date, only a few cases of M. parascrofulaceum infection have been reported (3)(4)(5)(6)(7)(8)(9)(10)(11), and the infection has not yet been clinically characterized completely.…”

“…M. parascrofulaceum, which belongs to Runyon group II (scotochromogens), was first reported in 2004 by Turenne et al ( 3 ) and was observed in only 1 of the 4,069 clinical isolates in an epidemiological study ( 4 ). The precise identification of mycobacterial species is important because the clinical courses and treatments vary according to the species.…”

First Case of Pulmonary Mycobacterium parascrofulaceum Infection in a Patient With Bronchiectasis in Korea

“…Mycobacterium parascrofulaceum is a member of slow-growing scotochromogenic nontuberculous mycobacteria (NTM) that can cause opportunistic infections in immunocompromised patients [ 1 ]. Only a few clinical infections with this strain have been reported to date [ 1 , 2 , 3 , 4 ]. We describe a case of M. parascrofulaceum pulmonary infection in a patient with bronchiectasis.…”